title: Characterization of the I-E(d)--restricted peptide recognized by an anti-idiotypic CD4+ T cell line.
abstract: We have previously reported a CD3+ CD4+ CD8- T cell line, J-2R which specifically recognized J558 individual idiotope (IdI) of anti-alpha (1-->3) dextran antibodies in an I-E(d) restricted manner. The J-2R proliferated in response to J558 IdI-derived peptides; however, the ability of the peptides to evoke the proliferation of J-2R was different. In the present study, we investigated the interaction between J558 IdI-derived peptides and I-E(d) molecules in competition experiments using a M104E IdI-derived peptide, M88-105. The M88-105 inhibited the proliferation of J-2R induced by J558 IdI-derived peptides. Furthermore, the proliferation induced by the peptides J92-109 and J96-105 was inhibited by the M88-105 at much lower inhibitor/antigenic peptide ratios, compared to the proliferation induced by the J88-105. Thus, shift of the framework to C-terminus and deletion of N-terminus amino acid residues from the 18-mer peptide J88-105 made the peptides more susceptible to the inhibition by the M88-105. Sequencing of the J-2R T cell receptor (TcR) revealed that J-2R used TcR, V alpha 1, J alpha 44; V beta 15, D beta 1, J beta 1.5. These results suggest that the peptides, J88-105, J92-109 and J96-105, directly bind to I-E(d) molecules, and that the capacity of J558 IdI-derived peptides to activate J-2R depends on the affinity to the I-E(d) molecules.
authors.affiliation: Department of Microbiology, Kinki University School of Medicine, Osaka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Masaki
authors.forename: S
authors.initials: S
authors.lastname: Yamane
authors.forename: K
authors.initials: K
authors.lastname: Irimajiri
authors.forename: A
authors.initials: A
authors.lastname: Horiuchi
authors.forename: J
authors.initials: J
authors.lastname: Yamaguchi
authors.forename: R
authors.initials: R
authors.lastname: Suzuki
authors.forename: I
authors.initials: I
authors.lastname: Kurane
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology; D001483:Base Sequence; D001667:Binding, Competitive; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D002460:Cell Line; D003911:Dextrans / Q000276:immunology; D015329:Gene Rearrangement, T-Lymphocyte; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D007140:Immunoglobulin Fab Fragments / Q000276:immunology; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D008213:Lymphocyte Activation; D051379:Mice; D008969:Molecular Sequence Data; D009194:Myeloma Proteins / Q000276:immunology; D010446:Peptide Fragments / Q000276:immunology*; D011485:Protein Binding; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics; D016415:Sequence Alignment
chemical_list: D000912:Antibodies, Neoplasm; D003911:Dextrans; D000949:Histocompatibility Antigens Class II; C024138:I-E-antigen; D007140:Immunoglobulin Fab Fragments; D007130:Immunoglobulin Idiotypes; D009194:Myeloma Proteins; D010446:Peptide Fragments; D016693:Receptors, Antigen, T-Cell, alpha-beta; C040834:alpha-1,3-dextran